Our Impact
120K+
Compounds Screened
25+
Active Assay Programs
15+
Peer-Reviewed Outputs
Therapeutic Focus
Targeting Unmet Needs
We concentrate on critical therapeutic areas, leveraging open-access platforms to address biology with significant clinical potential.
Early-Stage Oncology
Neurodegenerative Diseases
Rare Target Biology
Advancing novel small molecules and biologics against emerging cancer targets.
Developing new therapeutic strategies for debilitating neurological conditions.
Unlocking pathways for diseases with limited treatment options and high unmet need.
Our Guiding Principle
Open Science. Uncompromised Rigor. No Commercial Bias.
IDDI operates as a non-profit, ensuring scientific integrity and collaborative progress remain at the forefront of every discovery.
Join us in accelerating the journey from bench discovery to clinical impact. Explore our collaborative research programs.